Monthly PubMed Review

Home » Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer 

May 2019

Would you like to receive our monthly PubMed Review in your inbox?

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition. Chen X1,2,3, Wu Q1,2,3, Chen Y1,2,3, et al. Br J Pharmacol. 2019 Jun;176(12):2079-2094. doi: 10.1111/bph.14652. Epub 2019 May 11.

High developmental pluripotency‑associated 4 expression promotes cell proliferation and glycolysis, and predicts poor prognosis in non‑small‑cell lung cancer. Li L1, Wang Y2, Wang Q3, et al. Mol Med Rep. 2019 May 22. doi: 10.3892/mmr.2019.10272. [Epub ahead of print]

Subcellular compartmentalization of PKM2 identifies anti-PKM2 therapy response in vitro and in vivo mouse model of human non-small-cell lung cancer. Suzuki A1, Puri S2, Leland P1, Puri A1, Moudgil T2, Fox BA2,3, Puri RK1, Joshi BH1. PLoS One. 2019 May 23;14(5):e0217131. doi: 10.1371/journal.pone.0217131. eCollection 2019.

The effect of mouse strain, sex and carcinogen dose on toxicity and the development of lung dysplasia and squamous cell carcinomas in mice. Riolobos L1, Gad EA2, Treuting PM3, et al. Cancer Prev Res (Phila). 2019 May 17. pii: canprevres.0442.2018. doi: 10.1158/1940-6207.CAPR-18-0442. [Epub ahead of print]

SCREENING, DIAGNOSIS, BIOMARKER TESTING, AND STAGING

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer. Fintelmann FJ1, Troschel FM2, Kuklinski MW2, et al. Oncologist. 2019 May 31. pii: theoncologist.2019-0158. doi: 10.1634/theoncologist.2019-0158. [Epub ahead of print]

Determining malignancy in CT guided fine needle aspirate biopsy of subsolid lung nodules: Is core biopsy necessary? Kiranantawat N1, McDermott S1, Petranovic M1, et al. Eur J Radiol Open. 2019 May 4;6:175-181. doi: 10.1016/j.ejro.2019.04.006. eCollection 2019.

Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Pennell NA1, Arcila ME2, Gandara DR3, West H4. Am Soc Clin Oncol Educ Book. 2019 Jan;39:531-542. doi: 10.1200/EDBK_237863. Epub 2019 May 17.

Investigation of Low-Dose CT Lung Cancer Screening Scan “Over-Range” Issue Using Machine Learning Methods. Huo D1, Kiehn M2, Scherzinger A3. J Digit Imaging. 2019 May 17. doi: 10.1007/s10278-019-00233-z. [Epub ahead of print]

Effectiveness of Lung Cancer Screening Implementation in the Community Setting in the United States. Copeland A1, Criswell A1, Ciupek A1, King JC1. J Oncol Pract. 2019 May 31:JOP1800788. doi: 10.1200/JOP.18.00788. [Epub ahead of print]

Assessing Eligibility for Lung Cancer Screening Among Women Undergoing Screening Mammography: Cross-Sectional Survey Results From the National Health Interview Survey. López D1, Flores EJ2, Miles RC2, Wang G2, Glover M 4th3, Shepard JA2, Lehman CD2, Narayan AK4. J Am Coll Radiol. 2019 May 8. pii: S1546-1440(19)30439-9. doi: 10.1016/j.jacr.2019.04.006. [Epub ahead of print]

Diagnostic Performance of Radial Probe Endobronchial Ultrasound without a Guide-Sheath and the Feasibility of Molecular Analysis. Moon SM1, Choe J1, Jeong BH1, Um SW1, Kim H1, Kwon OJ1, Lee K2. Tuberc Respir Dis (Seoul). 2019 May 31. doi: 10.4046/trd.2018.0082. [Epub ahead of print]

Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Jain D1, Nambirajan A1, Borczuk A2, et al. Cancer Cytopathol. 2019 May;127(5):325-339. doi: 10.1002/cncy.22137. Epub 2019 May 3.

Low Rates of Patient-Reported Physician-Patient Discussion about Lung Cancer Screening among Current Smokers: Data from Health Information National Trends Survey. Huo J1, Hong YR2, Bian J3, Guo Y3, Wilkie DJ4, Mainous AG 3rd2. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):963-973. doi: 10.1158/1055-9965.EPI-18-0629.

NSCLC SURGERY

Clinical features of HIV-infected patients with non-small-cell lung cancer after lung resection. Asakawa A1, Horio H2, Yamamichi T2, Okui M2, Harada M2. Gen Thorac Cardiovasc Surg. 2019 May 31. doi: 10.1007/s11748-019-01149-9. [Epub ahead of print]

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database. Bailey KL1, Merchant N1, Seo YJ1, Elashoff D2, Benharash P1,3, Yanagawa J4,5. World J Surg. 2019 May;43(5):1377-1384. doi: 10.1007/s00268-018-04900-0.

Persistent opioid use is associated with worse survival after lobectomy for stage i non-small cell lung cancer. Nelson DB1, Cata JP2, Niu J3, et al. Pain. 2019 May 29. doi: 10.1097/j.pain.0000000000001630. [Epub ahead of print]

Outcomes Of Uniportal Vs Multiportal Video-Assisted Thoracoscopic Lobectomy. Bourdages-Pageau E1, Vieira A1, Lacasse Y1, Figueroa PU2. Semin Thorac Cardiovasc Surg. 2019 May 28. pii: S1043-0679(19)30170-4. doi: 10.1053/j.semtcvs.2019.05.021. [Epub ahead of print]

Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort. Osarogiagbon RU1, Lee YS2, Faris NR3, Ray MA2, Ojeabulu PO3, Smeltzer MP2. J Thorac Cardiovasc Surg. 2019 May 2. pii: S0022-5223(19)30968-7. doi: 10.1016/j.jtcvs.2019.04.068. [Epub ahead of print]

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Schoenfeld AJ1, Arbour KC1, Rizvi H1, Iqbal AN1, Gadgeel SM2, Girshman J3, Kris MG1, Riely GJ1, Yu HA1, Hellmann MD1. Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304). Song Y1, Wu YL2, Cao LJ3, et al. Am J Clin Oncol. 2019 May;42(5):432-439. doi: 10.1097/COC.0000000000000538.

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. Auliac JB1, Saboundji K2, Andre M3, et al. Target Oncol. 2019 May 22. doi: 10.1007/s11523-019-00646-4. [Epub ahead of print]

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy. Zhou Y1,2,3, Lin Z1,2,4, Zhang X1,2,5, Chen C1,2,6, Zhao H1,2,4, Hong S7,8,9, Zhang L10,11,12. J Immunother Cancer. 2019 May 3;7(1):120. doi: 10.1186/s40425-019-0600-6.

NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. Gubens MA, Davies M. J Natl Compr Canc Netw. 2019 May 1;17(5.5):574-578. doi: 10.6004/jnccn.2019.5005.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. West H1, McCleod M2, Hussein M3, et al. Lancet Oncol. 2019 May 20. pii: S1470-2045(19)30167-6. doi: 10.1016/S1470-2045(19)30167-6. [Epub ahead of print]

Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. Lau SC1, Chooback N2, Ho C3, Melosky B4. Clin Lung Cancer. 2019 May 11. pii: S1525-7304(19)30107-X. doi: 10.1016/j.cllc.2019.05.003. [Epub ahead of print]

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Langer CJ1, Redman MW2, Wade JL 3rd3, Aggarwal C4, Bradley JD5, Crawford J6, Stella PJ7, Knapp MH8, Miao J2, Minichiello K2, Herbst RS9, Kelly K10, Gandara DR10, Papadimitrakopoulou VA11

Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Tsao AS1, Jolly S2, Lee JM3. Am Soc Clin Oncol Educ Book. 2019 Jan;39:553-562. doi: 10.1200/EDBK_237839. Epub 2019 May 17.

Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. Singhi EK1, Horn L1, Sequist LV2, Heymach J3, Langer CJ4. Am Soc Clin Oncol Educ Book. 2019 Jan;39:e187-e197. doi: 10.1200/EDBK_237821. Epub 2019 May 17.

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Chen Y1, Liu Q2, Chen Z3, et al. J Exp Clin Cancer Res. 2019 May 14;38(1):193. doi: 10.1186/s13046-019-1192-1.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Hastings K1, Yu H2,3, Wei W4, et al. Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141. [Epub ahead of print]

Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. Bagley SJ1,2, Talento S3, Mitra N4, Meropol NJ5,6, Cohen RB1,2, Langer CJ1,2, Vachani A1,7,8. Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.

Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). Spigel DR1, McCleod M2, Jotte RM3, et al. J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376-4. doi: 10.1016/j.jtho.2019.05.010. [Epub ahead of print]

Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. Fukui T1, Okuma Y2, Nakahara Y2, et al. Clin Lung Cancer. 2019 May;20(3):208-214.e2. doi: 10.1016/j.cllc.2018.04.021. Epub 2018 May 5.

NSCLC - RADIOTHERAPY

Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy. Kennedy WR1, Gabani P1, Nikitas J1, Samson PP1, Robinson CG1, Bradley JD1, Roach MC1. Clin Transl Radiat Oncol. 2019 Feb 21;16:1-6. doi: 10.1016/j.ctro.2019.02.004. eCollection 2019 May.

Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. Wang W1,2, Men Y1,3, Wang J1, et al. BMC Cancer. 2019 May 22;19(1):478. doi: 10.1186/s12885-019-5692-3.

Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. Cuccia F1, Mortellaro G2, Mazzola R3, et al. J Geriatr Oncol. 2019 May 20. pii: S1879-4068(18)30434-X. doi: 10.1016/j.jgo.2019.05.002. [Epub ahead of print]

Hypofractionated proton beam therapy for centrally located lung cancer. Nakamura N1, Hotta K1, Zenda S1, et al. J Med Imaging Radiat Oncol. 2019 May 30. doi: 10.1111/1754-9485.12901. [Epub ahead of print]

Sparing Cardiac Substructures with Optimized Volumetric Modulated Arc Therapy and Intensity-Modulated Proton Therapy in Thoracic Radiation for Locally Advanced Non-Small Cell Lung Cancer. Ferris MJ1, Sykes K2, Switchenko JM3, Kayode OA4, Wolf J4, Dang Q4, Press RH4, Curran WJ4, Higgins KA4. Pract Radiat Oncol. 2019 May 8. pii: S1879-8500(19)30125-0. doi: 10.1016/j.prro.2019.04.013. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients. Schild SE1, Zhao L2, Wampfler JA3, Daniels TB4, Sio T4, Ross HJ5, Paripati H5, Marks RS6, Yi J7, Liu H8, He Y9, Yang P10.

Emerging therapies for small cell lung cancer. Yang S1, Zhang Z1, Wang Q2. J Hematol Oncol. 2019 May 2;12(1):47. doi: 10.1186/s13045-019-0736-3.

Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients. Schild SE1, Zhao L2, Wampfler JA3, Daniels TB4, Sio T4, Ross HJ5, Paripati H5, Marks RS6, Yi J7, Liu H8, He Y9, Yang P10. Clin Lung Cancer. 2019 May 11. pii: S1525-7304(19)30111-1. doi: 10.1016/j.cllc.2019.05.007. [Epub ahead of print]

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Schulze AB1, Evers G2, Kerkhoff A3, Mohr M4, Schliemann C5, Berdel WE6, Schmidt LH7. Cancers (Basel). 2019 May 17;11(5). pii: E690. doi: 10.3390/cancers11050690.

Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. Zeng H1,2, Li R3, Hu C4, et al. JAMA Netw Open. 2019 May 3;2(5):e190103. doi: 10.1001/jamanetworkopen.2019.0103.

Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma. Hann CL1, Scherpereel A2,3, Hellyer JA4, Wakelee HA4. Am Soc Clin Oncol Educ Book. 2019 Jan;39:543-552. doi: 10.1200/EDBK_237847. Epub 2019 May 17.

Malignant Pleural Effusion at Presentation in Patients with Small-Cell Lung Cancer. Shojaee S1,2, Singh I3,4, Solsky I5,4, Nana-Sinkam P6. Respiration. 2019 May 23:1-5. doi: 10.1159/000499372. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Alessandrino F1,2, Sahu S2, Nishino M1,2, Adeni AE3, Tirumani SH1,2, Shinagare AB4,5, Awad MM3. Abdom Radiol (NY). 2019 May;44(5):1917-1927. doi: 10.1007/s00261-019-01935-2.

Stigma and Quality of Life in Patients With Advanced Lung Cancer. Johnson LA1, Schreier AM1, Swanson M1, Moye JP2, Ridner S2. Oncol Nurs Forum. 2019 May 1;46(3):318-328. doi: 10.1188/19.ONF.318-328.

National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. Smith CEP1, Kamal AH1, Kluger M2, Coke P3, Kelley MJ1,4. J Oncol Pract. 2019 May 2:JOP1800559. doi: 10.1200/JOP.18.00559. [Epub ahead of print]

Ten-Year Trends of Utilization of Palliative Care Services and Life-Sustaining Treatments and Hospital Costs Associated With Patients With Terminally Ill Lung Cancer in the United States From 2005 to 2014. Hwang J1,2, Shen J2, Kim SJ3, Chun SY2, Kioka M4, Sheraz F4, Kim P2, Byun D5, Yoo JW4. Am J Hosp Palliat Care. 2019 May 23:1049909119852082. doi: 10.1177/1049909119852082. [Epub ahead of print]

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. Miura S1, Naito T2, Mitsunaga S3, et al. BMC Cancer. 2019 May 31;19(1):528. doi: 10.1186/s12885-019-5762-6.

Dispositional mindfulness, self-compassion, and compassion from others as moderators between stress and depression in caregivers of patients with lung cancer. Hsieh CC1, Yu CJ2, Chen HJ3, Chen YW4, Chang NT1, Hsiao FH1,5. Psychooncology. 2019 May 13. doi: 10.1002/pon.5106. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Chinese Herbal Medicine (Xiaoaiping) Injections for Chemotherapy-Induced Thrombocytopenia: A Randomized, Controlled, Multicenter Clinical Trial. Qi S1,2,3,4, Li X1, Dong Q1, et al. J Altern Complement Med. 2019 Jun;25(6):648-655. doi: 10.1089/acm.2018.0470. Epub 2019 May 17.

Yi-qi-yang-yin-tian-sui-fang enhances cisplatin-induced tumor eradication and inhibits interleukin-7 reduction in non-small cell lung cancer. Ke B1, Wu X1, Yang Q2, Huang Y3, Wang F4, Gong Y5, Liu J5, Shi L6. Biosci Rep. 2019 May 28. pii: BSR20190052. doi: 10.1042/BSR20190052. [Epub ahead of print]

MISCELLANEOUS WORKS

Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Blumenthal GM1,2, Gong Y1, Kehl K3, et al. Ann Oncol. 2019 May 1;30(5):830-838. doi: 10.1093/annonc/mdz060.

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients. Mezquita L1, Benito A2, Ruano-Raviña A3, et al. Clin Lung Cancer. 2019 May 3. pii: S1525-7304(19)30100-7. doi: 10.1016/j.cllc.2019.04.009. [Epub ahead of print]

Molecular links between COPD and lung cancer: new targets for drug discovery? Caramori G1, Ruggeri P1, Mumby S2, et al. Expert Opin Ther Targets. 2019 Jun;23(6):539-553. doi: 10.1080/14728222.2019.1615884. Epub 2019 May 11.

Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. Coghill AE1,2, Han X3, Suneja G4, Lin CC3,5, Jemal A3, Shiels MS1. Cancer. 2019 May 3. doi: 10.1002/cncr.32158. [Epub ahead of print]

An Insurer’s Program To Incentivize Generic Oncology Drugs Did Not Alter Treatment Patterns Or Spending On Care. Yasaitis L1, Gupta A2, Newcomb C3, Kim E4, Newcomer L5, Bekelman J6. Health Aff (Millwood). 2019 May;38(5):812-819. doi: 10.1377/hlthaff.2018.05083.

Archives